Table 1. Bacterial strains and plasmids used in this study.
| Strain or Plasmid | Relevant Characteristicsa | Source or Reference |
| B. cenocepacia | ||
| K56-2 | ET12 clone related to J2315, CF clinical Isolate, GmR | BCRRCa |
| MH1K | K56-2, ΔamrABC (BCAL1674–1676); GmS | [28] |
| ΔT2SS | Strain JST178; MH1K derivative with ΔgspL (BCAL3516), defective in T2SS, GmS | This study |
| ΔT4SS-1 | Strain JST17; K56-2 derivative carrying ΔpBCA017–59 and ΔamrABC (BCAL1674–1676),defective in T4SS-1, GmS | This study |
| ΔT4SS-2 | Strain JST39; MH1K derivative with ΔBCAM0324–0335), defective in T4SS-2, GmS | This study |
| ΔT3SS | JST40; MH1K derivative with ΔBCAM2040–2057, defective in T3SS, GmS | This study |
| ΔfliCD | JST114; K56-2 derivative with ΔfliCD and ΔamrABC (BCAL1674–1676), defective inflagellin, GmS | This study |
| T6SS+ | Strain JST143; K56-2 derivative with ΔatsR and ΔamrABC (BCAL1674–1676), defective in negative regulator of T6SS expression, GmS | This study |
| T6SS+-ΔT2SS | Strain JST143 derivative with ΔgspFED (BCAL3525–3527), defective in T2SS, GmS | This study |
| ΔT6SS | JST144; K56-2 derivative with ΔatsR, ΔbcsJ (hcp; BCAL0343), and ΔamrABC(BCAL1674–1676), defective in T6SS, GmS | This study |
| ΔT3SS-ΔfliCD | JST188; JST114 derivative with ΔBCAM2045–2057, defective in flagellin and T3SS, GmS | This study |
| ΔT2SS-ΔT6SS | JST198; MH1K derivative with ΔgspL (BCAL3516) and ΔbcsJ (hcp; BCAL0343),defective in T2SS and T6SS, GmS | This study |
| ΔT2SS-ΔT6SS | JST144 derivative with ΔgspFED (BCAL3525–3527), also defective in T2SS, GmS | This study |
| T6SS+-ΔzmpA | MH1K derivative with ΔatsR and ΔzmpA, defective in ZmpA production, GmS | This study |
| T6SS+-ΔzmpB | MH1K derivative with ΔatsR and ΔzmpB, defective in ZmpB production, GmS | This study |
| T6SS+-ΔzmpAB | MH1K derivative with ΔatsR, ΔzmpA, and ΔzmpB, defective in ZmpA and ZmpB production, GmS | This study |
| ΔT6SS-ΔzmpAB | MH1K derivative; ΔatsR, ΔzmpA, ΔzmpB, and ΔbcsJ (hcp; BCAL0343), defective in ZmpA and ZmpBproduction and in T6SS, GmS | This study |
| ΔT6SS-ΔT2SS-ΔzmpAB | MH1K derivative; ΔatsR, ΔzmpA, ΔzmpB, ΔbcsJ (hcp; BCAL0343), and ΔgspFED(BCAL3525–3527), defective in ZmpA and ZmpB production, in T6SS, and in T2SS, GmS | This study |
| E. coli | ||
| DH5α | F- φ80lacZ M15 endA1 recA1 supE44 hsdR17(rK- mK+) deoRthi-1 nupG supE44 gyrA96 relA1 Δ(lacZYA-argF)U169, λ– | Laboratory stock |
| SY327 | araD, Δ(lac pro) argE(Am) recA56 rifR nalA, λ pi | [58] |
| Plasmids | ||
| pDAI-SceI | oripBBR1, TetR, Pdhfr, mob+, expressing I-SceI restriction enzyme | [56] |
| pDSredT3 | Expresses Red fluorescent protein, CmR | |
| pGPI-SceI | oriR6K, ΩTpR, mob+, I-SceI restriction site | [56] |
| pMS107 | pIC20H derivative, contains a 1.3 kb fragment encoding the adenylcyclase fromB. pertussis, CyaA’ (aa 2–405), AmpR | [43] |
| pRK2013 | ori colE1, RK2 derivative, KanR, mob +, tra + | [55] |
| pSCrhaB2 | Cloning vector inducible with rhamnose, oripBBR1, rhaR rhaS PrhaB TpR mob+ | [57] |
| pSCrha-cyaA’ | Cloning vector, derivative of pSCrhaB2, inducible with rhamnose used to createC-terminal fusions with CyaA’ | This study |
| pZmpA-cyaA’ | zmpA in pSCrha-cyaA’, CyaA’ fused to the C-terminus of ZmpA | This Study |
| pZmpB-cyaA’ | zmpB in pSCrha-cyaA’, CyaA’ fused to the C-terminus of ZmpB | This Study |
a
Amp, ampicillin; BCRRC, B. cepacia complex Research and Referral Repository for Canadian CF Clinics; Cm, chloramphenicol; Gm, gentamicin; Kan, kanamycin; Tp, trimethoprim;; Tet, tetracycline; T2SS, Type II secretion system; T6SS, Type VI secretion system.